Company registration number 09183845 (England and Wales)
BIO TECH PHARMA LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
BIO TECH PHARMA LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2
Notes to the financial statements
3 - 4
BIO TECH PHARMA LIMITED
COMPANY INFORMATION
- 1 -
Director
Mr L Campbell
Company number
09183845
Registered office
Quantum House
Hobson Industrial Estate
Hobson
Newcastle Upon Tyne
England
NE16 6EA
Accountants
Consilium Audit Limited
169 West George Street
Glasgow
Scotland
G2 2LB
BIO TECH PHARMA LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2023
31 December 2023
- 2 -
2023
2022
Notes
£
£
£
£
Current assets
Cash at bank and in hand
100
100
Net current assets
100
100
Capital and reserves
-
-
Called up share capital
3
100
100

For the financial year ended 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 26 June 2024
Mr L Campbell
Director
Company Registration No. 09183845
BIO TECH PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
- 3 -
1
Accounting policies
Company information

Bio Tech Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Quantum House, Hobson Industrial Estate, Hobson, Newcastle Upon Tyne, England, NE16 6EA. The company's registration number is 09183845.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Reporting period

The company prepares the financial statements for a 12 month period to 31 December 2023. The comparative figrues are for the 15 month period to 31 December 2022.

1.3
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Total
-
0
-
0
3
Called up share capital
2023
2022
£
£
Ordinary share capital
Issued and fully paid
100 Ordinary shares of £1
100
100
BIO TECH PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 4 -
4
Ultimate controlling party

The Company is a wholly owned subsidiary of Target Healthcare Group Limited. The company is included within the consolidated financial statements of Target Healthcare Group Limited, available at the registered address 8 Redwood Crescent, East Kilbride, Glasgow, Scotland, G74 5PA.

 

The ultimate parent company is Target Healthcare Group Limited, a company registered in the Isle of Man. No consolidated accounts are required at this level.

 

The ultimate controlling party is L Campbell.

2023-12-312023-01-01trueCCH SoftwareCCH Accounts Production 2024.200Mr L Campbellfalsefalse091838452023-01-012023-12-3109183845bus:Director12023-01-012023-12-3109183845bus:RegisteredOffice2023-01-012023-12-31091838452023-12-31091838452022-12-3109183845core:ShareCapital2023-12-3109183845core:ShareCapital2022-12-31091838452021-09-012022-12-3109183845bus:EntityHasNeverTraded2023-01-012023-12-3109183845bus:PrivateLimitedCompanyLtd2023-01-012023-12-3109183845bus:FRS1022023-01-012023-12-3109183845bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3109183845bus:FullAccounts2023-01-012023-12-31xbrli:purexbrli:sharesiso4217:GBP